Loading
Journal of AIDS and HIV Treatment
ISSN: 2688-7436
Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF)
HIV infection in pregnancy continues to be of significant clinical and public health importance [1,2]. The current statistics published by the World Health Organization (WHO) demonstrate that 38 million people are living with HIV in 2019, and 1.1 million (85%) pregnant women living with HIV received antiretroviral therapy (ARVs) during pregnancy and postpartum.
J AIDS HIV Treat, 2022, Volume 4, Issue 1, p6-13 | DOI: 10.33696/AIDS.4.026Toward Personalized Medicine for HIV/AIDS
In 2019, approximately 38 million people were infected with HIV worldwide [1]. Although there is still no cure that successfully eradicates the disease, combination antiretroviral therapy (cART) has improved to a point where undetectable viral loads have become achievable and HIV carriers often live almost normal lives with very substantially increased average life expectancies compared to historical data.
J AIDS HIV Treat, 2021, Volume 3, Issue 2, p37-41 | DOI: 10.33696/AIDS.3.020Fostemsavir in Heavily Treatment-Experienced Individuals Living with HIV-1: Insights from the Phase 3 BRIGHTE Study
Fostemsavir (Rukobia™, ViiV Healthcare, Research Triangle Park, NC), a prodrug of the first-in-class attachment inhibitor temsavir, was developed to provide a much-needed new therapeutic option for heavily treatment-experienced (HTE) people living with HIV-1 (PLWH) who are unable to form a suppressive regimen from remaining viable antiretroviral (ARV) agents because of multidrug resistance, contraindications, prior intolerance, or other safety considerations.
J AIDS HIV Treat, 2021, Volume 3, Issue 2, p31-36 | DOI: 10.33696/AIDS.3.019Pre-Exposure Prophylaxis (PrEP) Safety and Tolerability in Individuals ≥ 45 Years Old
Pre-exposure prophylaxis (PrEP) is a combination of antiretroviral medications, most commonly prescribed as two co-formulated antiretrovirals, taken as a single tablet daily to significantly reduce the risk of human immunodeficiency virus (HIV) infection in individuals at high risk.
J AIDS HIV Treat, 2021, Volume 3, Issue 2, p27-30 | DOI: 10.33696/AIDS.3.018Early Insights into COVID-19 in Persons Living with HIV and Cardiovascular Manifestations
At the end of 2019, a novel coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei Province of China.
J AIDS HIV Treat, 2020, Volume 2, Issue 2, p68-74 | DOI: 10.33696/AIDS.2.010Assessment of Attitudes toward HIV and AIDS among Undergraduate Students at a Historically Black University
HIV is no longer only a public health challenge, but also a global threat with a devastating negative impact that has claimed over 35 million lives globally. In 2017, about 36.9 million people live with HIV, and 1.8 million people becoming newly infected with the disease globally [1].
J AIDS HIV Treat, 2019, Volume 1, Issue 2, p25-32 | DOI: 10.33696/AIDS.1.006Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.